Following the study that the dyslipidemia treatment fenofibrate is effective in diabetic retinopathy, this time, a study result showed that the combination of a statin and a combination treatment increased the effect.
The results of a study on the correlation between fenofibrate and statin administration and the incidence of diabetic retinopathy, conducted by Professor Nam-hoon Kim of the Department of Endocrinology at Korea University Anam Hospital, were presented at the annual meeting of the European Association for Diabetes (EASD) on the 21st.
Although Fenofibrate was developed as a treatment for dyslipidemia, the ACCORD clinical trial that looked at the risk of diabetes mellitus and the FIELD trial that looked at reducing the incidence of diabetes with fenofibrate showed that it reduced the effect of diabetic retinopathy, raising expectations for the addition of indications.
The research team randomly assigned 23,692 Koreans and 46,223 Koreans with type 2 diabetes over the age of 30 who received statins for at least 90 days after diagnosis 1:2 (statin + phenofibrate or statin), respectively, and followed them up for 10 years. observed.
The primary endpoint of the study was the composite outcome of the progression of diabetic retinopathy. As a result of the analysis, the incidence of the progression of diabetic retinopathy was 14.3 per 1000 person-years in the statin-only group and 12.7 per 1000 person-years with statin plus fenofibrate. The hazard ratio (HR) in the combination group was 0.89, which decreased by about 11%.
The risk of vitreous hemorrhage was reduced by 13% in both the statin alone group and the statin + fenofibrate group (HR 0.87), and the incidence of laser photocoagulation (HR 0.89) and in vivo injection treatment (HR 0.78) was similarly reduced.
The researchers analyzed the data according to the presence or absence of early retinopathy.
“We found evidence of fenofibrate benefits in people with early retinopathy, but not in people without retinopathy,” the researchers report.